Results from the LATAM subset in EGFR‐mutated NSCLC patients (n = 175) who received TKIs showed mPFS and mOS of 13 months (95% CI, 11.2–14.8) and 36 months (95% CI, 25.4–46.5), respectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.